EDMONTON, Alberta, March 28, 2012 (GLOBE NEWSWIRE) -- Isotechnika Pharma Inc. (TSX:ISA) (“Isotechnika” or the “Company”) announced today that, further to its press release of January 31, 2012, it has received notification that ILJIN Life Science Co., Ltd. (“ILJIN”) has submitted a request for arbitration relating to Isotechnika’s termination of their Development, Distribution and License Agreement (the “DDL”).
